Andrea de Bartolomeis - Publications

Affiliations: 
Neuroscience University School of Medicine of Naples Federico II Italy 
Area:
Schizophrenia, psychosis, antipsychotics, synapse, Homer

144/215 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Lamsma J, Raine A, Kia SM, Cahn W, Arold D, Banaj N, Barone A, Brosch K, Brouwer R, Brunetti A, Calhoun VD, Chew QH, Choi S, Chung YC, Ciccarelli M, ... ... de Bartolomeis A, et al. Structural brain abnormalities and aggressive behaviour in schizophrenia: Mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium. Medrxiv : the Preprint Server For Health Sciences. PMID 38370846 DOI: 10.1101/2024.02.04.24302268  0.701
2024 Fornaro M, Caiazza C, Billeci M, Berk M, Marx W, Balanzá-Martínez V, De Prisco M, Pezone R, De Simone G, Solini N, Iasevoli F, Berna F, Fond G, Boyer L, Carvalho AF, ... ... de Bartolomeis A, et al. Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis. Research Square. PMID 38260297 DOI: 10.21203/rs.3.rs-3787917/v1  0.673
2023 Omlor W, Rabe F, Fuchs S, Cecere G, Homan S, Surbeck W, Kallen N, Georgiadis F, Spiller T, Seifritz E, Weickert T, Bruggemann J, Weickert C, Potkin S, Hashimoto R, ... ... de Bartolomeis A, et al. Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study. Biorxiv : the Preprint Server For Biology. PMID 37961617 DOI: 10.1101/2023.09.22.559032  0.713
2023 Jiang Y, Luo C, Wang J, Palaniyappan L, Chang X, Xiang S, Zhang J, Duan M, Huang H, Gaser C, Nemoto K, Miura K, Hashimoto R, Westlye LT, Richard G, ... ... de Bartolomeis A, et al. Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia. Medrxiv : the Preprint Server For Health Sciences. PMID 37873296 DOI: 10.1101/2023.10.11.23296862  0.716
2023 Vellucci L, Ciccarelli M, Buonaguro EF, Fornaro M, D'Urso G, De Simone G, Iasevoli F, Barone A, de Bartolomeis A. The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. Biomolecules. 13. PMID 37627285 DOI: 10.3390/biom13081220  0.763
2023 Rossano F, Caiazza C, Zotti N, Viacava L, Irano A, Solini N, Pistone L, Pezone R, Cilmi F, Ricci C, De Prisco M, Iasevoli F, Kishi T, Solmi M, de Bartolomeis A, et al. The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 76: 23-51. PMID 37544075 DOI: 10.1016/j.euroneuro.2023.07.008  0.657
2023 D'Urso G, Magliacano A, Dell'Osso B, Lamberti H, Luciani A, Mariniello TS, Pomes MV, Rifici LM, Iasevoli F, de Bartolomeis A. Effects of strict COVID-19 lockdown on patients with obsessive-compulsive disorder compared to a clinical and a nonclinical sample. European Psychiatry : the Journal of the Association of European Psychiatrists. 66: e45. PMID 37258286 DOI: 10.1192/j.eurpsy.2023.2416  0.673
2023 D'Urso G, Pomes MV, Magliacano A, Iuliano C, Lamberti H, Manzo M, Mariniello TS, Iasevoli F, de Bartolomeis A. Depression and Anxiety Symptoms "Among the Waves" of the COVID-19 Pandemic in Obsessive Compulsive Disorder and Adjustment Disorder Patients. Healthcare (Basel, Switzerland). 11. PMID 37174803 DOI: 10.3390/healthcare11091261  0.668
2023 De Simone G, Mazza B, Vellucci L, Barone A, Ciccarelli M, de Bartolomeis A. Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment. Antioxidants (Basel, Switzerland). 12. PMID 37107350 DOI: 10.3390/antiox12040975  0.337
2023 Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cattaneo CI, Van den Eynde V, Birkenhager TK, Ruhé HG, Stahl S, Iasevoli F, de Bartolomeis A. Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 72: 60-78. PMID 37087864 DOI: 10.1016/j.euroneuro.2023.03.012  0.673
2023 de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia. International Journal of Molecular Sciences. 24. PMID 36983018 DOI: 10.3390/ijms24065945  0.398
2023 Iasevoli F, Avagliano C, D'Ambrosio L, Barone A, Ciccarelli M, De Simone G, Mazza B, Vellucci L, de Bartolomeis A. Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal. Biomedicines. 11. PMID 36979877 DOI: 10.3390/biomedicines11030895  0.73
2023 Barone A, De Simone G, Ciccarelli M, Buonaguro EF, Tomasetti C, Eramo A, Vellucci L, de Bartolomeis A. A Postsynaptic Density Immediate Early Gene-Based Connectome Analysis of Acute NMDAR Blockade and Reversal Effect of Antipsychotic Administration. International Journal of Molecular Sciences. 24. PMID 36901803 DOI: 10.3390/ijms24054372  0.658
2023 Tranfa M, Iasevoli F, Cocozza S, Ciccarelli M, Barone A, Brunetti A, de Bartolomeis A, Pontillo G. Neural substrates of verbal memory impairment in schizophrenia: A multimodal connectomics study. Human Brain Mapping. PMID 36852587 DOI: 10.1002/hbm.26248  0.663
2023 de Bartolomeis A, Vellucci L, De Simone G, Mazza B, Barone A, Ciccarelli M. Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics' Treatment of Schizophrenia. Cells. 12. PMID 36831241 DOI: 10.3390/cells12040574  0.35
2022 de Bartolomeis A, De Simone G, Ciccarelli M, Castiello A, Mazza B, Vellucci L, Barone A. Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance. Biomedicines. 10. PMID 36551939 DOI: 10.3390/biomedicines10123183  0.809
2022 de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opinion On Pharmacotherapy. 23: 2035-2052. PMID 36368055 DOI: 10.1080/14656566.2022.2145884  0.819
2022 D'Urso G, Toscano E, Barone A, Palermo M, Dell'Osso B, Di Lorenzo G, Mantovani A, Martinotti G, Fornaro M, Iasevoli F, de Bartolomeis A. Transcranial direct current stimulation for bipolar depression: systematic reviews of clinical evidence and biological underpinnings. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 121: 110672. PMID 36332699 DOI: 10.1016/j.pnpbp.2022.110672  0.797
2022 Somma T, Esposito F, Scala MR, Scelzo A, Baiano C, Patti S, Meglio V, Iasevoli F, Cavallo LM, Solari D, De Bartolomeis A, Cappabianca P, D'Urso G. Psychiatric Symptoms in Parkinson's Disease Patients before and One Year after Subthalamic Nucleus Deep Brain Stimulation Therapy: Role of Lead Positioning and Not of Total Electrical Energy Delivered. Journal of Personalized Medicine. 12. PMID 36294782 DOI: 10.3390/jpm12101643  0.682
2022 Iasevoli F, D'Ambrosio L, Ciccarelli M, Barone A, Gaudieri V, Cocozza S, Pontillo G, Brunetti A, Cuocolo A, de Bartolomeis A, Pappatà S. Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study. Schizophrenia Bulletin. PMID 36268829 DOI: 10.1093/schbul/sbac147  0.802
2022 Barone A, De Prisco M, Altavilla B, Avagliano C, Balletta R, Buonaguro EF, Ciccarelli M, D'Ambrosio L, Giordano S, Latte G, Matrone M, Milandri F, Francesco DN, Vellucci L, de Bartolomeis A. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach. Journal of Psychiatric Research. 155: 572-578. PMID 36206601 DOI: 10.1016/j.jpsychires.2022.09.044  0.799
2022 de Bartolomeis A, Barone A, Vellucci L, Mazza B, Austin MC, Iasevoli F, Ciccarelli M. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review. Molecular Neurobiology. PMID 35963926 DOI: 10.1007/s12035-022-02976-3  0.834
2022 Oliva V, De Prisco M, Pons-Cabrera MT, Guzmán P, Anmella G, Hidalgo-Mazzei D, Grande I, Fanelli G, Fabbri C, Serretti A, Fornaro M, Iasevoli F, de Bartolomeis A, Murru A, Vieta E, et al. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. Journal of Clinical Medicine. 11. PMID 35887699 DOI: 10.3390/jcm11143935  0.685
2022 de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics. Biomolecules. 12. PMID 35883465 DOI: 10.3390/biom12070909  0.804
2022 de Bartolomeis A, Vellucci L, Barone A, Manchia M, De Luca V, Iasevoli F, Correll CU. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. Pharmacology & Therapeutics. 108236. PMID 35764175 DOI: 10.1016/j.pharmthera.2022.108236  0.831
2022 Barone A, Billeci M, D'Amore S, De Prisco M, De Simone G, Ermini E, Freda V, Iannotta F, Luciani A, Pistone L, Rifici LM, Saia VM, Spennato G, Subosco F, Vellucci L, ... ... de Bartolomeis A, et al. The effects of sustained COVID-19 emergency and restrictions on the mental health of subjects with serious mental illness: A prospective study. Journal of Community Psychology. PMID 35615854 DOI: 10.1002/jcop.22886  0.775
2022 D'Urso G, Magliacano A, Rotbei S, Iasevoli F, de Bartolomeis A, Botta A. Predicting the Severity of Lockdown-Induced Psychiatric Symptoms with Machine Learning. Diagnostics (Basel, Switzerland). 12. PMID 35454005 DOI: 10.3390/diagnostics12040957  0.7
2022 de Bartolomeis A, Barone A, Buonaguro EF, Tomasetti C, Vellucci L, Iasevoli F. The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular "Lego" in the pathophysiology of psychiatric disorders. A systematic review and translational insight. Neuroscience and Biobehavioral Reviews. 136: 104596. PMID 35248676 DOI: 10.1016/j.neubiorev.2022.104596  0.804
2022 De Rosa A, Fontana A, Nuzzo T, Garofalo M, Di Maio A, Punzo D, Copetti M, Bertolino A, Errico F, Rampino A, de Bartolomeis A, Usiello A. Machine Learning algorithm unveils glutamatergic alterations in the post-mortem schizophrenia brain. Npj Schizophrenia. 8: 8. PMID 35217646 DOI: 10.1038/s41537-022-00231-1  0.45
2022 de Bartolomeis A, Barone A, Begni V, Riva MA. Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharmacological Research. 176: 106078. PMID 35026403 DOI: 10.1016/j.phrs.2022.106078  0.799
2022 Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, Gabaglio C, Lombardozzi G, Trovini G, Amici E, Perrini F, De Persis S, Iasevoli F, De Filippis S, de Bartolomeis A. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 114: 110493. PMID 34883221 DOI: 10.1016/j.pnpbp.2021.110493  0.719
2021 D'Urso G, Toscano E, Sanges V, Sauvaget A, Sheffer CE, Riccio MP, Ferrucci R, Iasevoli F, Priori A, Bravaccio C, de Bartolomeis A. Cerebellar Transcranial Direct Current Stimulation in Children with Autism Spectrum Disorder: A Pilot Study on Efficacy, Feasibility, Safety, and Unexpected Outcomes in Tic Disorder and Epilepsy. Journal of Clinical Medicine. 11. PMID 35011884 DOI: 10.3390/jcm11010143  0.684
2021 Fornaro M, Carvalho AF, De Prisco M, Mondin AM, Billeci M, Selby P, Iasevoli F, Berk M, Castle DJ, de Bartolomeis A. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 132: 289-303. PMID 34838527 DOI: 10.1016/j.neubiorev.2021.11.039  0.691
2021 Fornaro M, Trinchillo A, Saccà F, Iasevoli F, Nolano M, de Bartolomeis A. Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion On Pharmacotherapy. 1-8. PMID 34530652 DOI: 10.1080/14656566.2021.1980537  0.651
2021 Iasevoli F, Razzino E, Altavilla B, Avagliano C, Barone A, Ciccarelli M, D'Ambrosio L, Matrone M, Milandri F, Notar Francesco D, Fornaro M, de Bartolomeis A. Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia. Early Intervention in Psychiatry. PMID 33998142 DOI: 10.1111/eip.13174  0.809
2021 Barone A, Signoriello S, Latte G, Vellucci L, Giordano G, Avagliano C, Buonaguro EF, Marmo F, Tomasetti C, Iasevoli F, de Bartolomeis A. Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: translational inference from a postsynaptic density Immediate-Early Gene-based network analysis. Behavioural Brain Research. 113160. PMID 33577880 DOI: 10.1016/j.bbr.2021.113160  0.805
2020 Iasevoli F, Barone A, Buonaguro EF, Vellucci L, de Bartolomeis A. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opinion On Drug Safety. PMID 32892632 DOI: 10.1080/14740338.2020.1820985  0.787
2020 Iasevoli F, Buonaguro EF, Avagliano C, Barone A, Eramo A, Vellucci L, de Bartolomeis A. The Effects of Antipsychotics on the Synaptic Plasticity Gene Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. International Journal of Molecular Sciences. 21. PMID 32756473 DOI: 10.3390/Ijms21155555  0.807
2020 Fornaro M, Fusco A, Novello S, Mosca P, Anastasia A, De Blasio A, Iasevoli F, de Bartolomeis A. Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases. Frontiers in Psychiatry. 11: 438. PMID 32670098 DOI: 10.3389/Fpsyt.2020.00438  0.665
2020 de Bartolomeis A, Manchia M, Marmo F, Vellucci L, Iasevoli F, Barone A. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. Frontiers in Psychiatry. 11: 369. PMID 32477178 DOI: 10.3389/Fpsyt.2020.00369  0.827
2020 Iasevoli F, Fornaro M, D'Urso G, Galletta D, Casella C, Paternoster M, Buccelli C, de Bartolomeis A. Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine. 1-3. PMID 32423496 DOI: 10.1017/S0033291720001841  0.63
2019 de Bartolomeis A, Avagliano C, Vellucci L, D'Ambrosio L, Manchia M, D'Urso G, Buonaguro EF, Iasevoli F. Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neuroscience and Biobehavioral Reviews. PMID 31461641 DOI: 10.1016/J.Neubiorev.2019.08.019  0.831
2019 Buonaguro EF, Morley-Fletcher S, Avagliano C, Vellucci L, Iasevoli F, Bouwalerh H, Van Camp G, Nicoletti F, Maccari S, de Bartolomeis A. Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109725. PMID 31404590 DOI: 10.1016/J.Pnpbp.2019.109725  0.795
2019 Avagliano C, Iasevoli F, Buonaguro E, Vellucci L, De Bartolomeis A. Duration of antipsychotic treatment and doses/receptor profile modulate early gene expression throughout rat brain regions European Neuropsychopharmacology. 29: S610-S611. DOI: 10.1016/J.Euroneuro.2018.11.899  0.702
2018 Iasevoli F, Avagliano C, Altavilla B, Barone A, D'Ambrosio L, Matrone M, Notar Francesco D, Razzino E, de Bartolomeis A. Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs. Frontiers in Psychiatry. 9: 553. PMID 30429802 DOI: 10.3389/Fpsyt.2018.00553  0.803
2018 Iasevoli F, Avagliano C, Altavilla B, Barone A, Ciccarelli M, D'Ambrosio L, Notar Francesco D, Razzino E, Fornaro M, de Bartolomeis A. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses. Psychiatry Research. 269: 481-493. PMID 30195742 DOI: 10.1016/J.Psychres.2018.08.109  0.806
2018 Iasevoli F, D'Ambrosio L, Notar Francesco D, Razzino E, Buonaguro EF, Giordano S, Patterson TL, de Bartolomeis A. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients. Schizophrenia Research. PMID 29934250 DOI: 10.1016/J.Schres.2018.06.030  0.798
2018 Fornaro M, Anastasia A, Monaco F, Novello S, Fusco A, Iasevoli F, De Berardis D, Veronese N, Solmi M, de Bartolomeis A. Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders. 234: 131-138. PMID 29525354 DOI: 10.1016/J.Jad.2018.02.085  0.676
2018 de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Avvisati L, Latte G, Tomasetti C. Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29475793 DOI: 10.1016/J.Euroneuro.2018.01.006  0.806
2017 de Bartolomeis A, Buonaguro EF, Latte G, Rossi R, Marmo F, Iasevoli F, Tomasetti C. Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. Frontiers in Behavioral Neuroscience. 11: 240. PMID 29321734 DOI: 10.3389/Fnbeh.2017.00240  0.821
2017 Bernardo P, Galletta D, Iasevoli F, D'Ambrosio L, Troisi S, Gennaro E, Zara F, Striano S, de Bartolomeis A, Coppola A. CHD2 mutations: Only epilepsy? Description of cognitive and behavioral profile in a case with a new mutation. Seizure. 51: 186-189. PMID 28910737 DOI: 10.1016/J.Seizure.2017.09.001  0.62
2017 de Bartolomeis A, Prinzivalli E, Callovini G, D'Ambrosio L, Altavilla B, Avagliano C, Iasevoli F. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28887181 DOI: 10.1016/J.Pnpbp.2017.09.002  0.711
2017 Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, Buonaguro EF, Iasevoli F, Köhler CA, Carvalho AF, de Bartolomeis A. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. Biomed Research International. 2017: 3084859. PMID 28573138 DOI: 10.1155/2017/3084859  0.779
2017 Buonaguro EF, Iasevoli F, Marmo F, Eramo A, Latte G, Avagliano C, Tomasetti C, de Bartolomeis A. Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28235555 DOI: 10.1016/J.Pnpbp.2017.02.012  0.814
2017 de Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, Valchera A, Carano A, Vellante F, Marini S, Piersanti M, Perna G, Martinotti G, Di Giannantonio M. The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. International Journal of Molecular Sciences. 18. PMID 28208695 DOI: 10.3390/Ijms18020349  0.809
2017 Iasevoli F, Fagiolini A, Formato MV, Prinzivalli E, Giordano S, Balletta R, De Luca V, de Bartolomeis A. Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients. Psychiatry Research. 249: 159-166. PMID 28104562 DOI: 10.1016/J.Psychres.2017.01.015  0.714
2017 Tomasetti C, Iasevoli F, Buonaguro EF, De Berardis D, Fornaro M, Fiengo AL, Martinotti G, Orsolini L, Valchera A, Di Giannantonio M, de Bartolomeis A. Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. International Journal of Molecular Sciences. 18. PMID 28085108 DOI: 10.3390/Ijms18010135  0.824
2016 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Vellante F, Matarazzo I, Vecchiotti R, Perna G, Di Nicola M, Carano A, de Bartolomeis A, ... ... de Bartolomeis A, et al. Current and future perspectives on the Major Depressive Disorder: Focus on the new multimodal antidepressant Vortioxetine. Cns & Neurological Disorders Drug Targets. PMID 27781949 DOI: 10.2174/1871527315666161025140111  0.792
2016 De Berardis D, Fornaro M, Orsolini L, Iasevoli F, Tomasetti C, de Bartolomeis A, Serroni N, De Lauretis I, Girinelli G, Mazza M, Valchera A, Carano A, Vellante F, Matarazzo I, Perna G, et al. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. Cns Spectrums. 1-6. PMID 27702411 DOI: 10.1017/S1092852916000572  0.785
2016 Buonaguro EF, Tomasetti C, Chiodini P, Marmo F, Latte G, Rossi R, Avvisati L, Iasevoli F, de Bartolomeis A. Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. Journal of Psychopharmacology (Oxford, England). PMID 27443599 DOI: 10.1177/0269881116658987  0.829
2016 De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N, Mazza M, Valchera A, Fornaro M, Vecchiotti R, Carano A, Sepede G, Vellante F, Matarazzo I, Pompili M, et al. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. Current Pharmaceutical Design. PMID 27396597 DOI: 10.1016/J.Eurpsy.2016.01.563  0.739
2016 de Bartolomeis A, Marmo F, Buonaguro EF, Latte G, Tomasetti C, Iasevoli F. Switching antipsychotics: imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27177972 DOI: 10.1016/J.Pnpbp.2016.04.015  0.817
2016 Palazzo E, Luongo L, Guida F, Marabese I, Romano R, Iannotta M, Rossi F, D'Aniello A, Stella L, Marmo F, Usiello A, de Bartolomeis A, Maione S, de Novellis V. D-Aspartate drinking solution alleviates pain and cognitive impairment in neuropathic mice. Amino Acids. PMID 27115160 DOI: 10.1007/S00726-016-2205-4  0.62
2016 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Bonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant Vortioxetine. Expert Review of Neurotherapeutics. PMID 27050932 DOI: 10.1586/14737175.2016.1173545  0.785
2016 Buonaguro E, Latte G, Avvisati L, Marmo F, Iasevoli F, Tomasetti C, De Bartolomeis A. P.1.009 Effects of caffeine, nicotine and their combination with haloperidol on PSD molecules: relevance to psychiatric diseases European Neuropsychopharmacology. 26: S10-S11. DOI: 10.1016/S0924-977X(16)70012-5  0.753
2016 Buonaguro E, Iasevoli F, Latte G, Avagliano C, Vellucci L, Marmo F, Tomasetti C, De Bartolomeis A. Analysis of Homer1a expression levels as a tool to investigate antipsychotic-related perturbation of synaptic plasticity: translational implications for schizophrenia treatment strategies European Neuropsychopharmacology. 26: S233. DOI: 10.1016/S0924-977X(16)31095-1  0.813
2016 Latte G, Iasevoli F, Buonaguro E, Tomasetti C, Marmo F, Avagliano C, Vellucci L, De Bartolomeis A. Haloperidol modulates functional connectivity in the glutamate system: a postsynaptic density immediate-early gene-based network approach European Neuropsychopharmacology. 26: S224-S225. DOI: 10.1016/S0924-977X(16)31081-1  0.775
2015 de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. Cns Drugs. 29: 773-99. PMID 26346901 DOI: 10.1007/S40263-015-0278-3  0.824
2015 Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, De Berardis D, Tomasetti C, de Bartolomeis A. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 65: 34-48. PMID 26320028 DOI: 10.1016/J.Pnpbp.2015.08.010  0.8
2015 De Berardis D, Orsolini L, Serroni N, Girinelli G, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Valchera A, Fornaro M, Perna G, Piersanti M, Di Nicola M, Cavuto M, Martinotti G, et al. A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder. Cns & Neurological Disorders Drug Targets. PMID 26295824 DOI: 10.2174/1871527314666150821103825  0.775
2015 Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F, Belardo C, Marabese I, D'Aniello A, De Gregorio D, Rossi F, Piscitelli F, Lattanzi R, de Bartolomeis A, Usiello A, et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Molecular Brain. 8: 47. PMID 26260027 DOI: 10.1186/S13041-015-0139-5  0.588
2015 Serchov T, Clement HW, Schwarz MK, Iasevoli F, Tosh DK, Idzko M, Jacobson KA, de Bartolomeis A, Normann C, Biber K, van Calker D. Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. Neuron. 87: 549-62. PMID 26247862 DOI: 10.1016/J.Neuron.2015.07.010  0.68
2015 de Bartolomeis A, Errico F, Aceto G, Tomasetti C, Usiello A, Iasevoli F. D-aspartate dysregulation in Ddo(-/-) mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 62: 35-43. PMID 25979765 DOI: 10.1016/J.Pnpbp.2015.05.003  0.815
2015 De Berardis D, Marini S, Serroni N, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Tempesta D, Valchera A, Fornaro M, Pompili M, Sepede G, Vellante F, Orsolini L, Martinotti G, et al. Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. Current Drug Targets. 16: 1094-106. PMID 25944011 DOI: 10.2174/1389450116666150506114108  0.779
2015 Fornaro M, De Berardis D, Mazza M, Pino M, Favaretto E, Bedani F, Wieser C, Indelicato L, Paternò VF, Lo Monaco F, Dugo F, Ventriglio A, Mungo S, Selle V, Valchera A, ... ... De Bartolomeis A, et al. Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Journal of Affective Disorders. 178: 112-20. PMID 25805403 DOI: 10.1016/J.Jad.2015.03.001  0.765
2015 Errico F, D'Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, Napolitano F, Angrisano T, Di Maio A, Keller S, Vitucci D, Galbusera A, Chiariotti L, Bertolino A, de Bartolomeis A, et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Translational Psychiatry. 5: e512. PMID 25689573 DOI: 10.1016/S0924-9338(15)31301-8  0.728
2015 de Bartolomeis A, Iasevoli F, Marmo F, Buonaguro EF, Eramo A, Rossi R, Avvisati L, Latte G, Tomasetti C. Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 566-82. PMID 25649681 DOI: 10.1016/J.Euroneuro.2015.01.003  0.815
2015 De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, Srinivasan V, Iasevoli F, Tomasetti C, De Bartolomeis A, Valchera A, Perna G, Mazza M, Di Nicola M, Martinotti G, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. International Journal of Molecular Sciences. 16: 1111-30. PMID 25569089 DOI: 10.3390/Ijms16011111  0.79
2015 Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F, Belardo C, Marabese I, D'Aniello A, De Gregorio D, Rossi F, Piscitelli F, Lattanzi R, De Bartolomeis A, Usiello A, et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice Molecular Brain. 8. DOI: 10.1186/s13041-015-0139-5  0.581
2015 de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Cns Drugs. DOI: 10.1007/s40263-015-0278-3  0.699
2014 de Bartolomeis A, Iasevoli F, Tomasetti C, Buonaguro EF. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. Molecular Neurobiology. PMID 25394379 DOI: 10.1007/S12035-014-8962-8  0.811
2014 Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment. 10: 1867-78. PMID 25285010 DOI: 10.2147/NDT.S61672  0.303
2014 Quarantelli M, Palladino O, Prinster A, Schiavone V, Carotenuto B, Brunetti A, Marsili A, Casiello M, Muscettola G, Salvatore M, de Bartolomeis A. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. Biomed Research International. 2014: 325052. PMID 25157354 DOI: 10.1155/2014/325052  0.68
2014 Iasevoli F, Buonaguro EF, Sarappa C, Marmo F, Latte G, Rossi R, Eramo A, Tomasetti C, de Bartolomeis A. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 299-314. PMID 25025505 DOI: 10.1016/J.Pnpbp.2014.07.003  0.826
2014 Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Current Neuropharmacology. 12: 219-38. PMID 24851087 DOI: 10.2174/1570159X12666140324183406  0.831
2014 Buonaguro EF, Cimmarosa S, de Bartolomeis A. Dandy-Walker syndrome with psychotic symptoms: a case report. Rivista Di Psichiatria. 49: 100-2. PMID 24770576 DOI: 10.1708/1461.16151  0.727
2014 Iasevoli F, Buonaguro EF, Marconi M, Di Giovambattista E, Rapagnani MP, De Berardis D, Martinotti G, Mazza M, Balletta R, Serroni N, Di Giannantonio M, de Bartolomeis A, Valchera A. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. Isrn Pharmacology. 2014: 762127. PMID 24592333 DOI: 10.1155/2014/762127  0.79
2014 de Bartolomeis A, Buonaguro EF, Iasevoli F, Tomasetti C. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. Journal of Psychopharmacology (Oxford, England). 28: 505-526. PMID 24554693 DOI: 10.1177/0269881114523864  0.818
2014 de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Molecular Neurobiology. 49: 484-511. PMID 23999870 DOI: 10.1007/S12035-013-8534-3  0.829
2014 Marmo F, Buonaguro E, Latte G, Iasevoli F, De Bartolomeis A. P.3.c.008 Immediate early and constitutive genes expression in antipsychotic switching paradigm: from clinical practice to animal model European Neuropsychopharmacology. 24: S519. DOI: 10.1016/S0924-977X(14)70831-4  0.769
2014 Iasevoli F, Tomasetti C, Buonaguro EF, Latte G, Rossi R, Avvisati L, Avagliano C, Fico G, Mazzola G, Marmo F, de Bartolomeis A. Poster #T100 MINOCYCLINE ADD-ON TO HALOPERIDOL BLUNTS HALOPERIDOL-MEDIATED EXPRESSION OF EARLY GENES IMPLICATED IN GLUTAMATERGIC NEUROTRANSMISSION IN BOTH VEHICLE AND KETAMINE-TREATED RATS Schizophrenia Research. 153: S325. DOI: 10.1016/S0920-9964(14)70917-X  0.776
2014 Iasevoli F, Giordano S, Balletta R, Buonaguro EF, Tomasetti C, Rossi R, Gilardi V, Cucciniello C, Elce C, Acampora R, de Bartolomeis A. Poster #M252 PATIENTS' OPINIONS ON KEY ISSUES OF PSYCHOSOCIAL FUNCTIONING AMONG NON-PSYCHOTICS PSYCHOTIC RESPONDERS AND NON-RESPONDERS: CORRELATION WITH CLINICAL VARIABLES AND SYMPTOM DOMAINS RELEVANT TO REMISSION FROM PSYCHOSIS Schizophrenia Research. 153: S281. DOI: 10.1016/S0920-9964(14)70802-3  0.667
2014 Iasevoli F, Giordano S, Balletta R, Avvisati L, Latte G, Gilardi V, Buonaguro EF, Formato M, Prinzivalli E, Rossi R, de Bartolomeis A. Poster #S257 TOUCHING BY HAND HOW PSYCHOTIC FEATURES TRANSLATE INTO WORSE LIFE CONDITIONS: THE RELATION OF KEY PSYCHOSOCIAL ISSUES WITH CLINICAL VARIABLES IN NON-PSYCHOTIC, PSYCHOTIC RESPONDER, AND PSYCHOTIC NON-RESPONDER PATIENTS Schizophrenia Research. 153: S183. DOI: 10.1016/S0920-9964(14)70536-5  0.66
2013 Iasevoli F, Balletta R, Gilardi V, Giordano S, de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatric Disease and Treatment. 9: 1113-20. PMID 23950651 DOI: 10.2147/NDT.S47571  0.683
2013 de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Research. 210: 387-95. PMID 23910239 DOI: 10.1016/J.Psychres.2013.06.042  0.815
2013 Iasevoli F, Aloj L, Latte G, Avvisati L, Marmo F, Tomasetti C, Buonaguro EF, Simeoli C, Pivonello R, Colao A, de Bartolomeis A. The glucocorticoid analog dexamethasone alters the expression and the distribution of dopamine receptors and enkephalin within cortico-subcortical regions. Current Molecular Pharmacology. 6: 149-55. PMID 23862670 DOI: 10.2174/187446720603140415215941  0.794
2013 Iasevoli F, Valchera A, Di Giovambattista E, Marconi M, Rapagnani MP, De Berardis D, Martinotti G, Fornaro M, Mazza M, Tomasetti C, Buonaguro EF, Di Giannantonio M, Perugi G, de Bartolomeis A. Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. Journal of Affective Disorders. 151: 540-50. PMID 23856282 DOI: 10.1016/J.Jad.2013.06.041  0.786
2013 de Bartolomeis A, Avvisati L, Iasevoli F, Tomasetti C. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. European Journal of Pharmacology. 718: 502-23. PMID 23834777 DOI: 10.1016/J.Ejphar.2013.06.034  0.811
2013 de Bartolomeis A, Sarappa C, Buonaguro EF, Marmo F, Eramo A, Tomasetti C, Iasevoli F. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 46: 1-12. PMID 23800465 DOI: 10.1016/J.Pnpbp.2013.06.010  0.825
2013 De Berardis D, Marini S, Iasevoli F, Tomasetti C, de Bartolomeis A, Mazza M, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Sepede G, Martinotti G, Di Giannantonio M. The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review. Cns & Neurological Disorders Drug Targets. 12: 252-64. PMID 23469841 DOI: 10.2174/1871527311312020012  0.807
2013 de Bartolomeis A, Marmo F, Buonaguro EF, Rossi R, Tomasetti C, Iasevoli F. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1516-29. PMID 23357084 DOI: 10.1016/J.Euroneuro.2012.11.014  0.819
2013 de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology. 225: 1-19. PMID 23179966 DOI: 10.1007/S00213-012-2921-8  0.719
2013 Iasevoli F, Tomasetti C, de Bartolomeis A. Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochemical Research. 38: 1-22. PMID 22991141 DOI: 10.1007/S11064-012-0886-Y  0.785
2013 Iasevoli F, Avvisati L, Latte G, Buonaguro EF, Tomasetti C, Aloj L, De Bartolomeis A. Differential adaptive changes in dopaminergic system by acute vs. subchronic ketamine: Relevance for psychosis pathophysiology and treatment Current Signal Transduction Therapy. 8: 119-128. DOI: 10.2174/15743624113086660004  0.683
2013 Buonaguro E, Marmo F, Sarappa C, Eramo A, Tomasetti C, Iasevoli F, De Bartolomeis A. P.1.g.054 Gene-expression imaging by N-methyl-D-aspartate receptor antagonists: implications for dopamine–glutamate interplay in psychosis European Neuropsychopharmacology. 23: S220-S221. DOI: 10.1016/S0924-977X(13)70341-9  0.789
2012 de Bartolomeis A, Tomasetti C. Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. Molecular Neurobiology. 46: 275-96. PMID 22763587 DOI: 10.1007/s12035-012-8293-6  0.681
2012 Iasevoli F, Latte G, Avvisati L, Sarappa C, Aloj L, de Bartolomeis A. The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis. Journal of Neuroscience Research. 90: 1756-67. PMID 22605548 DOI: 10.1002/Jnr.23071  0.687
2012 de Bartolomeis A, Sarappa C, Magara S, Iasevoli F. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. European Journal of Pharmacology. 682: 1-11. PMID 22387855 DOI: 10.1016/J.Ejphar.2012.02.033  0.743
2012 de Bartolomeis A, Tomasetti C, Cicale M, Yuan PX, Manji HK. Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 22: 527-35. PMID 22245542 DOI: 10.1016/J.Euroneuro.2011.11.006  0.675
2012 Panariello F, Perruolo G, Cassese A, Giacco F, Botta G, Barbagallo AP, Muscettola G, Beguinot F, Formisano P, de Bartolomeis A. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. Journal of Cellular Physiology. 227: 1485-92. PMID 21618539 DOI: 10.1002/jcp.22864  0.583
2012 Iasevoli F, Balletta R, Giordano S, Buonaguro E, Latte G, de Bartolomeis A. P.3.c.043 Resistance to antipsychotics is associated with higher cognitive impairment compared to non-resistant schizophrenia European Neuropsychopharmacology. 22: S341-S342. DOI: 10.1016/S0924-977X(12)70527-8  0.691
2011 Iasevoli F, Cicale M, Abbott LC, de Bartolomeis A. Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: a model of spontaneously occurring motor disturbances. Neuroscience Letters. 503: 176-80. PMID 21884752 DOI: 10.1016/J.Neulet.2011.08.025  0.659
2011 Tomasetti C, Dell'Aversano C, Iasevoli F, Marmo F, de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35: 184-97. PMID 21055435 DOI: 10.1016/J.Pnpbp.2010.10.025  0.822
2011 Iasevoli F, Ambesi-Impiombato A, Fiore G, Panariello F, Muscettola G, de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. Journal of Psychopharmacology (Oxford, England). 25: 875-87. PMID 20147574 DOI: 10.1177/0269881109358199  0.805
2011 Calandro S, Avvisati L, Latte G, Patrì A, Rossi R, Buonaguro E, Sarappa C, Iasevoli F, Aloj L, de Bartolomeis A. P.1.032 Where and when ketamine alters the dopamine system: translational implications for drug addiction and psychoses European Neuropsychopharmacology. 21: S26-S27. DOI: 10.1016/S0924-977X(11)70031-1  0.674
2011 Marmo F, Latte G, Avvisati L, Patrì A, Rossi R, Buonaguro E, Tomasetti C, Iasevoli F, Aloj L, de Bartolomeis A. P.1.031 Expression of glucose metabolism genes in a psychosis model: a molecular link between NMDA receptor hypofunction and metabolism disorders? European Neuropsychopharmacology. 21: S25-S26. DOI: 10.1016/S0924-977X(11)70030-X  0.761
2010 Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology. 212: 329-44. PMID 20652539 DOI: 10.1007/S00213-010-1954-0  0.833
2010 Iasevoli F, Fiore G, Cicale M, Muscettola G, de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Research. 177: 255-60. PMID 20304506 DOI: 10.1016/J.Psychres.2010.02.009  0.825
2009 De Luca V, Annesi G, De Marco EV, de Bartolomeis A, Nicoletti G, Pugliese P, Muscettola G, Barone P, Quattrone A. HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. Neuropsychobiology. 59: 239-45. PMID 19648775 DOI: 10.1159/000230689  0.614
2009 Iasevoli F, Tomasetti C, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 33: 813-21. PMID 19243698 DOI: 10.1016/J.Pnpbp.2009.02.009  0.82
2009 Dell'aversano C, Tomasetti C, Iasevoli F, de Bartolomeis A. Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Research Bulletin. 79: 123-9. PMID 19189858 DOI: 10.1016/J.Brainresbull.2009.01.006  0.831
2008 Souza RP, De Luca V, Muscettola G, Rosa DV, de Bartolomeis A, Romano Silva M, Kennedy JL. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 1848-53. PMID 18793692 DOI: 10.1016/j.pnpbp.2008.08.014  0.62
2008 Iasevoli F, Ambesi-Impiombato A, Fiore G, Panariello F, Muscettola G, de Bartolomeis A. P.1.17 Topographical and temporal distribution of Homer1a expression is correlated to antipsychotics dopaminergic profile European Neuropsychopharmacology. 18: s15-s16. DOI: 10.1016/S0924-977X(08)70018-X  0.669
2007 Tomasetti C, Dell'Aversano C, Iasevoli F, de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. 150: 144-58. PMID 17916411 DOI: 10.1016/J.Neuroscience.2007.08.022  0.711
2007 Ambesi-Impiombato A, Panariello F, Dell'aversano C, Tomasetti C, Muscettola G, de Bartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse (New York, N.Y.). 61: 429-39. PMID 17372981 DOI: 10.1002/syn.20385  0.791
2007 Iasevoli F, Polese D, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis. Neuroscience Letters. 416: 1-5. PMID 17317002 DOI: 10.1016/J.Neulet.2007.01.041  0.822
2005 de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Current Pharmaceutical Design. 11: 3561-94. PMID 16248808 DOI: 10.2174/138161205774414538  0.737
2003 de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacology Bulletin. 37: 51-83. PMID 14608240  0.695
2003 Ambesi-Impiombato A, D'Urso G, Muscettola G, de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Research. Brain Research Protocols. 11: 189-96. PMID 12842224 DOI: 10.1016/S1385-299X(03)00056-4  0.616
2003 Fiore G, Cicale M, Magara S, Mondola R, Muscettola G, de Bartolomeis A. Antipsychotics with different D2 dopamine receptor potency affect differently the postsynaptic density protein homer at glutamatergic metabotropic synapse Schizophrenia Research. 60: 106. DOI: 10.1016/S0920-9964(03)80841-1  0.673
2003 Eramo A, Fiore G, Gentile S, Pellegrino F, Muscettola G, de Bartolomeis A. The forgotten therapy: Depot neuroleptics in the era of atypical antipsychotics, a community based study Schizophrenia Research. 60: 38. DOI: 10.1016/S0920-9964(03)80111-1  0.732
2002 Polese D, de Serpis AA, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 906-13. PMID 12464447 DOI: 10.1016/S0893-133X(02)00371-8  0.703
2002 Cicale M, Ambesi-Impiombato A, Cimini V, Fiore G, Muscettola G, Abbott LC, de Bartolomeis A. Decreased gene expression of calretinin and ryanodine receptor type 1 in tottering mice. Brain Research Bulletin. 59: 53-8. PMID 12372549 DOI: 10.1016/S0361-9230(02)00841-9  0.616
2002 de Bartolomeis A, Aloj L, Ambesi-Impiombato A, Bravi D, Caracò C, Muscettola G, Barone P. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Brain Research. Molecular Brain Research. 98: 124-9. PMID 11834303 DOI: 10.1016/S0169-328X(01)00327-8  0.698
2001 De Bartolomeis A, Polese D, Amato de Serpis A, Iasevoli F, Ambesi-Impiombato A, Galietta A, Muscettola G. NMDA receptor hypofunction: Cortical and subcortical CaMKII mRNA gene expression European Neuropsychopharmacology. 11: S290. DOI: 10.1016/S0924-977X(01)80381-3  0.782
2000 de Bartolomeis A, Aloj L, Ambesi A, Bravi D, Caraco C, Cicale M, Muscettola G, Barone P. Postsynaptic density protein gene expression after typical or atypical antipsychotics administration Schizophrenia Research. 41: 246. DOI: 10.1016/S0920-9964(00)90921-6  0.66
1997 De Bartolomeis A, Koprivica V, Pickar D, Crawley JN, Abbott LC. Opioidergic and dopaminergic gene expression in the caudate-putamen and accumbens of the mutant mouse, tottering (tg/tg). Brain Research. Molecular Brain Research. 46: 321-4. PMID 9191109 DOI: 10.1016/S0169-328X(97)00027-2  0.579
1997 Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 17: 437-47. PMID 9143226 DOI: 10.1097/00004647-199704000-00009  0.421
1997 Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America. 94: 2569-74. PMID 9122236 DOI: 10.1073/Pnas.94.6.2569  0.542
1995 Holmes PV, de Bartolomeis A, Koprivica V, Crawley JN. Lack of effect of chronic morphine treatment and naloxone-precipitated withdrawal on tyrosine hydroxylase, galanin, and neuropeptide Y mRNA levels in the rat locus coeruleus. Synapse (New York, N.Y.). 19: 197-205. PMID 7540319 DOI: 10.1002/syn.890190307  0.605
1995 Breier A, Carson R, Eckelman W, de Bartolomeis A, Saunders R, Weinberger D, Su T, Pickar D. In vivo estimates of synaptic dopamine concentrations with 11C-raclopride/pet: A direct test of the dopamine hypothesis Schizophrenia Research. 15: 76-77. DOI: 10.1016/0920-9964(95)95240-A  0.463
1994 de Bartolomeis A, Austin MC, Goodwin GA, Spear LP, Pickar D, Crawley JN. Dopaminergic and peptidergic mRNA levels in juvenile rat brain after prenatal cocaine treatment. Brain Research. Molecular Brain Research. 21: 321-32. PMID 7909578 DOI: 10.1016/0169-328X(94)90263-1  0.584
1990 Muscettola G, Barbato G, de Bartolomeis A, Monteleone P, Pickar D. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Research. 33: 259-67. PMID 2243901 DOI: 10.1016/0165-1781(90)90042-4  0.732
1989 Muscettola G, de Bartolomeis A, Barbato G, Nerozzi D. Plasma HVA in schizophreniform disorder and chronic schizophrenia Schizophrenia Research. 2: 169. DOI: 10.1016/0920-9964(89)90205-3  0.664
Low-probability matches (unlikely to be authored by this person)
2022 Di Maio A, De Rosa A, Pelucchi S, Garofalo M, Marciano B, Nuzzo T, Gardoni F, Isidori AM, Di Luca M, Errico F, De Bartolomeis A, Marcello E, Usiello A. Analysis of mRNA and Protein Levels of , and Genes in Post-Mortem Brain of Schizophrenia, Parkinson's and Alzheimer's Disease Patients. International Journal of Molecular Sciences. 23. PMID 35163460 DOI: 10.3390/ijms23031539  0.297
2012 de Bartolomeis A, Szumlinski KK. Group 1 metabotropic glutamate receptors and schizophrenia Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1: 94-103. DOI: 10.1002/wmts.15  0.297
2013 Errico F, Napolitano F, Squillace M, Vitucci D, Blasi G, de Bartolomeis A, Bertolino A, D'Aniello A, Usiello A. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. Journal of Psychiatric Research. 47: 1432-7. PMID 23835041 DOI: 10.1016/j.jpsychires.2013.06.013  0.292
2022 Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. Cns Drugs. 36: 659-679. PMID 35759211 DOI: 10.1007/s40263-022-00932-2  0.286
2018 Solmi M, Fornaro M, Toyoshima K, Carvalho AF, Köhler CA, Veronese N, Stubbs B, de Bartolomeis A, Correll CU. Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. Cns Spectrums. 1-17. PMID 30460884 DOI: 10.1017/S1092852918001050  0.281
2018 Bani-Fatemi A, Tasmim S, Graff A, Gerretsen P, Dada OO, Kennedy JL, Hettige N, Zai C, de Jesus D, de Bartolomeis A, De Luca V. The effect of ethnicity and immigration on treatment resistance in schizophrenia. Comprehensive Psychiatry. 89: 28-32. PMID 30579127 DOI: 10.1016/j.comppsych.2018.12.003  0.272
2004 Mondola R, Magara S, Eramo A, De Bartolomeis A. Augmentation therapy of antipsychotics by no conventional drugs in schizophrenia treatment | Terapia di potenziamento degli antipsicotici con farmaci non convenzionali nel trattamento della schizofrenia Italian Journal of Psychopathology. 10: 397-416.  0.272
2016 de Bartolomeis A, Fagiolini A, Vaggi M, Vampini C. Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment. 12: 99-108. PMID 26811682 DOI: 10.2147/NDT.S96214  0.268
2018 D'Urso G, Anastasia A, Toscano E, Patti S, de Bartolomeis A. Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. Experimental and Clinical Psychopharmacology. PMID 30035575 DOI: 10.1037/pha0000219  0.267
2018 Clerici M, de Bartolomeis A, De Filippis S, Ducci G, Maremmani I, Martinotti G, Schifano F. Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. Frontiers in Psychiatry. 9: 575. PMID 30483161 DOI: 10.3389/fpsyt.2018.00575  0.264
2022 Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppälä N, Howes OD. Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. Cns Drugs. PMID 35976566 DOI: 10.1007/s40263-022-00946-w  0.258
2008 Palumbo P, Eramo A, De Bartolomeis A. Janus's face of schizophrenia treatment: Neurobiology of antipsychotic treatments response and resistance | La testa di Giano del trattamento della schizofrenia: Neurobiologia della risposta e resistenza agli antipsicotici Rivista Di Psichiatria. 43: 269-291.  0.256
2016 Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503  0.254
2017 Benedetti F, Poletti S, Locatelli C, Mazza E, Lorenzi C, Vitali A, Riberto M, Brioschi S, Vai B, Bollettini I, Melloni E, Aggio V, Falini A, De Bartolomeis A, Colombo C. A Homer 1 gene variant influences brain structure and function, lithium effects on white matter, and antidepressant response in bipolar disorder: A multimodal genetic imaging study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 29079138 DOI: 10.1016/j.pnpbp.2017.10.011  0.249
2023 de Bartolomeis A, De Simone G, De Prisco M, Barone A, Napoli R, Beguinot F, Billeci M, Fornaro M. Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment. Molecular Psychiatry. PMID 37085712 DOI: 10.1038/s41380-023-02065-4  0.249
2019 Polese D, Fornaro M, Palermo M, De Luca V, de Bartolomeis A. Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis. Frontiers in Psychiatry. 10: 210. PMID 31057434 DOI: 10.3389/fpsyt.2019.00210  0.242
2012 de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opinion On Pharmacotherapy. 13: 2027-36. PMID 22946707 DOI: 10.1517/14656566.2012.719876  0.242
2019 Vellucci L, Avagliano C, Buonaguro E, Iasevoli F, De Bartolomeis A. P.117 Antipsychotic effects on the synaptic plasticity-related gene Homer1a are dependent on dose, receptor profile, timing of administration, and brain regions European Neuropsychopharmacology. 29: S98-S99. DOI: 10.1016/j.euroneuro.2019.09.172  0.241
2003 De Bartolomeis A, Tomasetti C. Schizophrenia and dopamine cortico-subcortical dysregulation: Molecolar implication for dopomine partial agonism therapy | Schizofrenia e disregolazione dopaminergica corticosottocorticale: Basi molecolari e correlati clinici dell'agonismo parziale dopaminergico come strategia terapeutica Italian Journal of Psychopathology. 9: 342-355.  0.239
2011 Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies. Schizophrenia Research and Treatment. 2011: 459284. PMID 22988505 DOI: 10.1155/2011/459284  0.239
2019 Fornaro M, Solmi M, Stubbs B, Veronese N, Monaco F, Novello S, Fusco A, Anastasia A, De Berardis D, Carvalho AF, de Bartolomeis A, Vieta E. Prevalence and correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents without dementia: systematic review and meta-analysis. The British Journal of Psychiatry : the Journal of Mental Science. 1-10. PMID 30864533 DOI: 10.1192/bjp.2019.5  0.23
2018 Perugi G, Vannucchi G, Barbuti M, Maccariello G, De Bartolomeis A, Fagiolini A, Maina G. Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers: a prospective observational study in Italy. International Clinical Psychopharmacology. PMID 29465467 DOI: 10.1097/YIC.0000000000000211  0.223
2019 Altamura AC, Buoli M, Cesana BM, Fagiolini A, de Bartolomeis A, Maina G, Bellomo A, Dell'Osso B. Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. The Australian and New Zealand Journal of Psychiatry. 4867418823268. PMID 30658550 DOI: 10.1177/0004867418823268  0.223
2018 Fornaro M, Anastasia A, Novello S, Fusco A, Pariano R, De Berardis D, Solmi M, Veronese N, Stubbs B, Vieta E, Berk M, de Bartolomeis A, Carvalho AF. The Emergence of loss of efficacy during Antidepressant Drug Treatment for Major Depressive Disorder: An Integrative Review of Evidence, Mechanisms, and Clinical Implications. Pharmacological Research. PMID 30385364 DOI: 10.1016/J.Phrs.2018.10.025  0.22
2016 de Bartolomeis A, Fagiolini A, Maina G. [Vortioxetine in the treatment of major depression]. Rivista Di Psichiatria. 51: 215-230. PMID 27996982 DOI: 10.1708/2596.26720  0.219
2020 Maccariello G, Barbuti M, Vannucchi G, De Bartolomeis A, Fagiolini A, Maina G, Perugi G. Predictors of Depressive Switch in Patients With Bipolar I Disorder Who Initiated or Changed Pharmacologic Treatment for Mania or Mixed-Mania: A Prospective Observational Study. The Journal of Clinical Psychiatry. 81. PMID 32526106 DOI: 10.4088/JCP.19m12896  0.217
2023 De Prisco M, Oliva V, Fico G, Radua J, Grande I, Roberto N, Anmella G, Hidalgo-Mazzei D, Fornaro M, de Bartolomeis A, Serretti A, Vieta E, Murru A. Emotion dysregulation in bipolar disorder compared to other mental illnesses: a systematic review and meta-analysis. Psychological Medicine. 1-20. PMID 37842774 DOI: 10.1017/S003329172300243X  0.215
2006 De Luca V, Zai G, Tharmalingam S, de Bartolomeis A, Wong G, Kennedy JL. Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 268-71. PMID 16274962 DOI: 10.1016/j.euroneuro.2005.09.007  0.207
2006 De Luca V, Tharmalingam S, Müller DJ, Wong G, de Bartolomeis A, Kennedy JL. Gene-gene interaction between MAOA and COMT in suicidal behavior: analysis in schizophrenia. Brain Research. 1097: 26-30. PMID 16725119 DOI: 10.1016/j.brainres.2006.04.053  0.2
2020 Buoli M, Cesana BM, Fagiolini A, Albert U, Maina G, de Bartolomeis A, Pompili M, Bondi E, Steardo L, Amore M, Bellomo A, Bertolino A, Di Nicola M, Di Sciascio G, Fiorillo A, et al. Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. Early Intervention in Psychiatry. PMID 33058435 DOI: 10.1111/eip.13051  0.191
2021 Perrini F, Matrone M, de Bartolomeis A, Montano A, Amici E, Callovini G, Cuomo I, de Persis S, Lombardozzi G, Battagliese G, Porrari R, Kotzalidis GD, De Filippis S. Developmental trajectories in psychiatric disorders: does substance/alcohol use moderate the effects of affective temperaments as moderators of age at onset? A study in post-acute, hospitalized patients with psychotic or DSM-5 bipolar or major depressive disorders. Journal of Addictive Diseases. 1-22. PMID 33587024 DOI: 10.1080/10550887.2021.1886568  0.191
2004 de Bartolomeis A, Fiore G. Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: implications for human behavior pathologies. International Review of Neurobiology. 59: 221-54. PMID 15006490 DOI: 10.1016/S0074-7742(04)59009-8  0.19
2023 De Prisco M, Oliva V, Fico G, Montejo L, Possidente C, Bracco L, Fortea L, Anmella G, Hidalgo-Mazzei D, Fornaro M, de Bartolomeis A, Serretti A, Murru A, Vieta E, Radua J. Differences in facial emotion recognition between bipolar disorder and other clinical populations: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 127: 110847. PMID 37625644 DOI: 10.1016/j.pnpbp.2023.110847  0.187
2020 Fornaro M, Carvalho AF, Fusco A, Anastasia A, Solmi M, Berk M, Sim K, Vieta E, de Bartolomeis A. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. Journal of Affective Disorders. 276: 970-983. PMID 32750614 DOI: 10.1016/J.Jad.2020.07.109  0.184
2019 Buoli M, Cesana BM, Dell'Osso B, Fagiolini A, de Bartolomeis A, Bondi E, Maina G, Bellomo A, Altamura AC. Gender-related differences in patients with bipolar disorder: a nationwide study. Cns Spectrums. 1-8. PMID 30905327 DOI: 10.1017/S1092852918001529  0.18
2021 Wang KZ, Dai N, Zai CC, de Bartolomeis A, Gerretsen P, Graff A, De Luca V. Recent Stressful Life Events and Suicidal Ideation in Schizophrenia: A 1-Year Follow-up Study. The Journal of Nervous and Mental Disease. PMID 34618715 DOI: 10.1097/NMD.0000000000001424  0.18
2021 Fornaro M, De Prisco M, Billeci M, Ermini E, Young AH, Lafer B, Soares JC, Vieta E, Quevedo J, de Bartolomeis A, Sim K, Yatham LN, Bauer M, Stein DJ, Solmi M, et al. Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. Journal of Affective Disorders. 295: 740-751. PMID 34517248 DOI: 10.1016/j.jad.2021.08.091  0.175
2015 D'Urso G, Brunoni AR, Anastasia A, Micillo M, de Bartolomeis A, Mantovani A. Polarity-dependent effects of transcranial direct current stimulation in obsessive-compulsive disorder. Neurocase. 1-5. PMID 25971992 DOI: 10.1080/13554794.2015.1045522  0.174
2017 Buonaguro E, Morley-Fletcher S, Avagliano C, Vellucci L, Maccari S, De Bartolomeis A. Early life stress affects glutamatergic postsynaptic density genes: implications for novel treatment targets European Neuropsychopharmacology. 27: S758-S759. DOI: 10.1016/S0924-977X(17)31388-3  0.172
2022 De Prisco M, Oliva V, Fico G, Fornaro M, de Bartolomeis A, Serretti A, Vieta E, Murru A. Defining clinical characteristics of emotion dysregulation in bipolar disorder: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews. 142: 104914. PMID 36243194 DOI: 10.1016/j.neubiorev.2022.104914  0.171
2018 DʼUrso G, Mantovani A, Patti S, Toscano E, de Bartolomeis A. Transcranial Direct Current Stimulation in Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, and Anxiety Disorders. The Journal of Ect. PMID 30095684 DOI: 10.1097/YCT.0000000000000538  0.17
2021 Buoli M, Cesana BM, Bolognesi S, Fagiolini A, Albert U, Di Salvo G, Maina G, de Bartolomeis A, Pompili M, Palumbo C, Bondi E, Steardo L, De Fazio P, Amore M, Altamura M, et al. Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study. European Archives of Psychiatry and Clinical Neuroscience. PMID 34652488 DOI: 10.1007/s00406-021-01343-y  0.169
2003 Celano E, Tiraboschi E, Consogno E, D'Urso G, Mbakop MP, Gennarelli M, de Bartolomeis A, Racagni G, Popoli M. Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs. Biological Psychiatry. 53: 442-9. PMID 12614997 DOI: 10.1016/S0006-3223(02)01491-9  0.166
2024 Oliva V, Possidente C, De Prisco M, Fico G, Anmella G, Hidalgo-Mazzei D, Murru A, Fanelli G, Fabbri C, Fornaro M, de Bartolomeis A, Solmi M, Radua J, Vieta E, Serretti A. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis. The Lancet. Psychiatry. 11: 210-220. PMID 38360024 DOI: 10.1016/S2215-0366(24)00006-3  0.166
2017 Altamura AC, Buoli M, Cesana B, Dell'Osso B, Tacchini G, Albert U, Fagiolini A, de Bartolomeis A, Maina G, Sacchetti E. Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study. European Archives of Psychiatry and Clinical Neuroscience. PMID 28365865 DOI: 10.1007/s00406-017-0791-0  0.166
2018 Fornaro M, Anastasia A, Novello S, Fusco A, Solmi M, Monaco F, Veronese N, De Berardis D, de Bartolomeis A. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disorders. PMID 29441650 DOI: 10.1111/bdi.12612  0.163
1992 Barone P, Palma V, de Bartolomeis A, Cicarelli G, Campanella G. Dopaminergic regulation of epileptic activity. Neurochemistry International. 20: 245S-249S. PMID 1365435 DOI: 10.1016/0197-0186(92)90246-N  0.162
2020 Galletta D, Califano AI, Micanti F, Santangelo G, Santoriello C, de Bartolomeis A. Cognitive correlates of borderline intellectual functioning in borderline personality disorder. Journal of Psychiatric Research. 130: 372-380. PMID 32882579 DOI: 10.1016/j.jpsychires.2020.06.016  0.162
2007 De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 697-704. PMID 17291373 DOI: 10.1017/S1461145707007547  0.161
2023 Fornaro M, Caiazza C, De Simone G, Rossano F, de Bartolomeis A. Insomnia and related mental health conditions: Essential neurobiological underpinnings towards reduced polypharmacy utilization rates. Sleep Medicine. 113: 198-214. PMID 38043331 DOI: 10.1016/j.sleep.2023.11.033  0.159
2006 Boscia F, Gala R, Pignataro G, de Bartolomeis A, Cicale M, Ambesi-Impiombato A, Di Renzo G, Annunziato L. Permanent focal brain ischemia induces isoform-dependent changes in the pattern of Na+/Ca2+ exchanger gene expression in the ischemic core, periinfarct area, and intact brain regions. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 26: 502-17. PMID 16107787 DOI: 10.1038/sj.jcbfm.9600207  0.154
2018 Fornaro M, De Berardis D, Anastasia A, Novello S, Fusco A, Cattaneo CI, Solmi M, Monaco F, Veronese N, Kim YK, de Bartolomeis A. The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention. Psychiatry Research. 269: 658-672. PMID 30216918 DOI: 10.1016/j.psychres.2018.08.034  0.153
2016 D'Urso G, Brunoni AR, Mazzaferro MP, Anastasia A, de Bartolomeis A, Mantovani A. Transcranial direct current stimulation for obsessive-compulsive disorder: A randomized, controlled, partial crossover trial. Depression and Anxiety. PMID 27802585 DOI: 10.1002/Da.22578  0.148
2023 Oliva V, De Prisco M, Fico G, Possidente C, Fortea L, Montejo L, Anmella G, Hidalgo-Mazzei D, Grande I, Murru A, Fornaro M, de Bartolomeis A, Dodd A, Fanelli G, Fabbri C, et al. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. PMID 37740499 DOI: 10.1111/acps.13618  0.133
2023 Fornaro M, Mondin AM, Billeci M, Fusco A, De Prisco M, Caizza C, Micanti F, Calati R, Carvalho AF, de Bartolomeis A. Psychopharmacology of eating disorders: Systematic review and meta-analysis of randomized controlled trials. Journal of Affective Disorders. PMID 37393954 DOI: 10.1016/j.jad.2023.06.068  0.131
1999 Barone P, Fiorillo C, Morone A, Vitale C, De Bartolomeis A. Changes in transcription activity in the rat brain following the acute administration of typical and atypical neuroleptics Italian Journal of Neurological Sciences. 20: 271-272.  0.131
2003 Eramo A, Fiore G, Gentile S, Pellegrino F, Muscettola G, De Bartolomeis A. Use of neuroleptic depot and switch to atypical antipsychotics in territorial practice. Implications for the pathophysiology of psychosis | Uso dei neurolettici depot e switch agli aps atipici nella pratica territoriale. Implicazioni per la fisiopatologia dei disturbi psicotici Italian Journal of Psychopathology. 9: 29-31.  0.13
2004 Tiraboschi E, Giambelli R, D'Urso G, Galietta A, Barbon A, de Bartolomeis A, Gennarelli M, Barlati S, Racagni G, Popoli M. Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. Neuroreport. 15: 2393-6. PMID 15640762 DOI: 10.1097/00001756-200410250-00018  0.128
2023 Fornaro M, Caiazza C, Solini N, De Prisco M, Billeci M, Vannini M, Shorr R, Caiolo S, Lussignoli M, Siskind D, Pigato G, Barone A, Sambataro F, de Bartolomeis A, Correll CU, et al. Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials. Molecular Psychiatry. PMID 37821573 DOI: 10.1038/s41380-023-02266-x  0.128
2018 Sauvaget A, Poulet E, Mantovani A, Bulteau S, Damier P, Moutaud B, Paternoster M, de Bartolomeis A, DʼUrso G. The Psychiatric Neuromodulation Unit: Implementation and Management. The Journal of Ect. PMID 29944606 DOI: 10.1016/J.Encep.2019.04.006  0.126
2019 Fornaro M, Sassi T, Novello S, Anastasia A, Fusco A, Senatore I, de Bartolomeis A. Prominent autistic traits and subthreshold bipolar/mixed features of depression in severe anorexia nervosa. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). PMID 31691722 DOI: 10.1590/1516-4446-2019-0500  0.126
2007 Panariello F, Perruolo G, Barbagallo APM, Cassese A, Formisano P, Muscettola G, De Bartolomeis A. Schizophrenia, antipsychotic agents and diabetes: The role of PED/PEA 15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 kDa) and AKT | Schizofrenia, antipsicotici e diabete: Ruolo di PED/PEA 15 e AKT Italian Journal of Psychopathology. 13: 455-457.  0.121
2024 Fornaro M, Caiazza C, Rossano F, Cilmi F, De Prisco M, Vieta E, Thompson T, Solmi M, Carvalho AF, Iasevoli F, de Bartolomeis A. Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 81: 53-63. PMID 38401406 DOI: 10.1016/j.euroneuro.2024.01.011  0.12
2017 D'Urso G, Dell'Osso B, Rossi R, Brunoni AR, Bortolomasi M, Ferrucci R, Priori A, de Bartolomeis A, Altamura AC. Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression. Journal of Affective Disorders. 219: 25-30. PMID 28505499 DOI: 10.1016/J.Jad.2017.05.019  0.119
1997 Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, de Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, Levine AS, Giordano A, Pass HI. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nature Medicine. 3: 908-12. PMID 9256284 DOI: 10.1038/Nm0897-908  0.114
2009 De Bartolomeis A. Translational neurobiology of psychosis and novel frontiers for the treatment: Controversial, successfull and inconstincency issues | Neurobiologia traslazionale delle psicosi e nuove frontiere nel trattamento: Controversie, successi e incongruenze Italian Journal of Psychopathology. 15: 107-110.  0.101
2008 Magara S, Cozzolino F, Muscettola G, de Bartolomeis A. Patient refractory to definition of drug-resistance criteria | Pazienti "resistenti" alla definizione dei criteri di farmacoresistenza Italian Journal of Psychopathology. 14: 235-237.  0.093
1994 Mohanakumar KP, de Bartolomeis A, Wu RM, Yeh KJ, Sternberger LM, Peng SY, Murphy DL, Chiueh CC. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation. Annals of the New York Academy of Sciences. 738: 392-9. PMID 7832447 DOI: 10.1111/J.1749-6632.1994.Tb21828.X  0.085
2015 De Bartolomeis A. C.14.02 Second witness – impact on brain architecture European Neuropsychopharmacology. 25: S675. DOI: 10.1016/S0924-977X(15)30973-1  0.075
2022 Fornaro M, Dragioti E, De Prisco M, Billeci M, Mondin AM, Calati R, Smith L, Hatcher S, Kaluzienski M, Fiedorowicz JG, Solmi M, de Bartolomeis A, Carvalho AF. Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials. Bmc Medicine. 20: 224. PMID 35818057 DOI: 10.1186/s12916-022-02423-z  0.067
1988 Tata F, Gori E, De Bartolomeis AM, Mari MV. [New therapeutic prospectives in Behçet's disease: beta-interferon]. Recenti Progressi in Medicina. 79: 135-7. PMID 3393721  0.031
Hide low-probability matches.